Opus Genetics (IRD) Payables (2010 - 2026)
Opus Genetics (IRD) posted quarterly Payables of $4.4 million for Q1 2026, down 70.8% year-over-year from $15.1 million in Q1 2025, and up 34.28% quarter-over-quarter from $3.3 million in Q4 2025.
Opus Genetics (IRD) Payables (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Payables for 17 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 70.8% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (down 70.8% YoY), while the FY2025 annual figure was $3.3 million, down 36.03% from the prior year.
- Payables climbed to $4.4 million in Q1 2026 per IRD's latest filing, from $3.3 million in the prior quarter.
- Across five years, Payables topped out at $23.7 million in Q3 2025 and bottomed at $708000.0 in Q2 2024.
- Historically, Payables has averaged $4.9 million across 5 years, with a median of $2.2 million in 2023.
- Annual changes were most pronounced in 2025 — Payables soared 2710.43% — and 2026, when it slumped 70.8%.
- Opus Genetics' Payables stood at $1.1 million in 2022, then surged by 108.33% to $2.2 million in 2023, then soared by 131.16% to $5.1 million in 2024, then sank by 36.03% to $3.3 million in 2025, then jumped by 34.28% to $4.4 million in 2026.
- Business Quant data shows IRD's Payables at $4.4 million in Q1 2026, $3.3 million in Q4 2025, and $23.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.88 Mn |
| Mar 31, 2026 | 4.42 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 23.72 Mn |
| Jun 30, 2025 | 13.27 Mn |
| Mar 31, 2025 | 15.15 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Sep 30, 2024 | 844,000.00 |
| Jun 30, 2024 | 708,000.00 |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 1.89 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Sep 30, 2021 | 1.43 Mn |